

ABSTRACT TEMPLATE for Company Presentations

Questions for categories: Biotech/Pharma Investment Rational

Omnix Medical, founded in 2015, is a privately-owned clinical-stage biotechnology company developing the next-generation antibiotics against Multi Drug Resistant (MDR) bacteria. Mimicking the innate immune system of insects to selectively kill resistant bacterial strains without toxic effects. We are addressing an enormous and rapidly growing market opportunity by developing an arsenal of antimicrobial peptides (AMPs) as therapeutic agents for treatment of life-threatening infections. In Omnix Medical, European Innovation Committee (EIC) Champion, 2020, secured €10.8M in funding for the clinical development of OMN6, with a top 1-percentile ranking.

○ **Business Strategy**

While the available drugs are failing and Antimicrobial Resistance (AMR) is spreading, Omnix Medical is in a position to mitigate the spread and evolution of resistance and save lives by introducing a safe and effective approach to treating infections in general. In opposite to currently available drugs, our life-saving therapies represent a novel antibiotic class with significantly diminished risk for triggering evolution of resistance, allowing physicians to prescribe it freely as first-line treatment.

○ **Core Technology**

We introduce drug-like peptides that effectively kill multi-drug resistant (MDR) bacteria, where other solutions fail, and actually lower the probability for the development of resistance. The unique Mechanism of Action employed by Omnix peptides avoids resistance and positions Omnix technology as the next Standard of Care (SoC) in severe, life-threatening infections.

○ **Product Profile/Pipeline**

Omnix maintains a pipeline of novel peptides, in various stages of development, addressing additional high priority resistant pathogens. OMN6, our lead compound, is a first-in-class antimicrobial peptide for the treatment of life-threatening infections caused by Gram-negative bacteria.

Currently, Omnix is conducting a Phase-I clinical trial with its lead compound OMN6. Trial is held in The Netherlands.

○ **What's Next?**

Completing Phase-I clinical trial with OMN6, achieving phase-II readiness for trials with OMN6, while advancing new compounds through our discovery programs and towards clinical development.